Chemotherapy-induced acceleration of DNA methylation-based biological age in breast cancer

Drew R. Nannini,Rene Cortese,Christopher VonTungeln,Gerhard C. Hildebrandt

DOI: https://doi.org/10.1080/15592294.2024.2360160

2024-06-02

Epigenetics

Abstract:Breast cancer is the most common cancer diagnosed in women and is often treated with chemotherapy. Although previous studies have demonstrated increasing biological age in patients who receive chemotherapy, evaluation of this association with DNA methylation-based markers of biological ageing may provide novel insight into the role of chemotherapy on the ageing process. We therefore sought to investigate the association between chemotherapy and markers of biological ageing as estimated from DNA methylation in women with breast cancer. DNA methylation profiling was performed on peripheral blood collected from 18 patients before and after the first cycle of chemotherapy using the Infinium HumanMethylation450 BeadChip. Six markers of biological age acceleration were estimated from DNA methylation levels. Multiple linear regression analyses were performed to evaluate the association between each metric of biological age acceleration and chemotherapy. After adjusting for chronological age and race, intrinsic epigenetic age acceleration ( p = 0.041), extrinsic epigenetic age acceleration ( p = 0.050), PhenoAge acceleration ( p = 0.001), GrimAge acceleration ( p < 0.001), and DunedinPACE ( p = 0.006) were significantly higher and telomere length ( p = 0.027) was significantly lower following the first cycle of chemotherapy compared to before treatment initiation. These results demonstrate greater biological ageing as estimated from DNA methylation following chemotherapy in women with breast cancer. Our findings illustrate that cytotoxic therapies may modulate the ageing process among breast cancer patients and may also have implications for age-related health conditions in cancer survivors.

genetics & heredity,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **The impact of chemotherapy on DNA - methylation - based biological age acceleration in breast cancer patients**.

### Specific problem description

1. **Background and motivation**:
- Breast cancer is the most common cancer among women and is usually treated with chemotherapy.
- Although chemotherapy is effective, some studies have shown that chemotherapy may accelerate the biological age of patients and increase age - related health problems.
- Researchers hope to gain in - depth understanding of the specific impact of chemotherapy on the aging process by evaluating DNA methylation markers, so as to provide new insights for the treatment and subsequent health management of breast cancer patients.

2. **Research objectives**:
- **Primary objective**: To explore whether chemotherapy will cause changes in the DNA methylation level of breast cancer patients, thereby accelerating their biological age.
- **Secondary objective**: To evaluate the changes of different types of DNA methylation markers (such as intrinsic epigenetic age acceleration, extrinsic epigenetic age acceleration, PhenoAge acceleration, GrimAge acceleration, and DunedinPACE) before and after chemotherapy, and analyze the relationship between these changes and chemotherapy.

3. **Research methods**:
- Peripheral blood samples of 18 breast cancer patients before and after the first chemotherapy cycle were collected.
- DNA methylation was analyzed using Infinium HumanMethylation450 BeadChip.
- Six different biological age acceleration indicators were calculated.
- Through multivariate linear regression analysis, the impact of chemotherapy on each biological age acceleration indicator was evaluated, while adjusting for the patients' actual age and ethnicity factors.

4. **Research results**:
- After adjusting for actual age and ethnicity, chemotherapy significantly accelerated the intrinsic epigenetic age (p = 0.041), the extrinsic epigenetic age (p = 0.050), PhenoAge (p = 0.001), GrimAge (p < 0.001), and DunedinPACE (p = 0.006), and significantly shortened telomere length (p = 0.027).
- These results indicate that chemotherapy has led to a significant acceleration of DNA - methylation - based biological age in breast cancer patients.

### Conclusions and significance

- **Conclusion**: Chemotherapy may accelerate the biological age of breast cancer patients by inducing changes in DNA methylation. This finding suggests that chemotherapy not only has a direct effect on tumors but may also have an impact on the long - term health of patients.
- **Significance**: Understanding the impact of chemotherapy on biological age is helpful for developing more effective treatment strategies, reducing the negative impact of chemotherapy on the long - term health of patients, and improving the quality of life of breast cancer survivors.

### Key formulas

- **Calculation of DNA methylation level**: The $\beta$ value is used to represent the DNA methylation level.
- **Estimation of biological age acceleration**: Calculated by a linear model, and the formula is:

\[
\text{Acceleration}=\text{Residual from linear model of chronological age on each biological metric}
\]

- **Multivariate linear regression analysis**: Used to evaluate the impact of chemotherapy on biological age acceleration indicators, and the formula is:

\[
Y_i=\beta_0+\beta_1X_i+\sum_{j = 1}^k\beta_jZ_{ij}+\epsilon_i
\]

where $Y_i$ is the biological age acceleration indicator, $X_i$ is the chemotherapy status, $Z_{ij}$ is the covariate (such as actual age, ethnicity, etc.), and $\epsilon_i$ is the error term.

Through these analyses, the researchers reached the conclusion that chemotherapy significantly accelerates the biological age of breast cancer patients.